Skip to main content
. 2020 Dec 17;9(12):4079. doi: 10.3390/jcm9124079

Table A2.

Baseline characteristics of patients with pre-existing diabetes vs. GC-induced diabetes.

All Patients with Hyperglycemia (n = 812) GC-Induced Diabetes (n = 399) Pre-Existing Diabetes and Hyperglycemia (n = 413) p-Value
Male sex, n (%) 356 (44%) 188 (47%) 168 (40.7%) 0.066
Age, y, mean (interquartile range) 68.5 (±13.4) 65.92 (±15.71) 71.03 (±10.14) <0.001
Clinical variables
Body mass index kg/m2 (IQR) 26.6 (23.4–31) 25.3 (22–29) 28 (24.78–32.6) <0.001
Mean glucocorticoid (GC) dose 1 mg/kg/day 1.22 (±3.3) 1.79 (±4.1) 0.66 (±2.2) <0.001
Duration of GC administration (in days) 5.12 (±2.1) 5.33 (±2.1) 4.92 (±2.2) 0.006
Length of stay 9.0 (6.0–15.0) 9.0 (5.0–15) 9.0 (6.0–15.0) 0.43
Charlson Comorbidity Index 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.049
Indication for GC administration 0.01
Autoimmune-inflammatory 300 (36.9%) 156 (39.1%) 144 (34.9%)
Oncology 175 (21.6%) 99 (24.8%) 76 (18.4%)
Pneumology/Infectiology 294 (36.2%) 123 (30.8%) 171 (41.4%)
Endocrinology/others 43 (5.3%) 21 (5.3%) 22 (5.3%)
Diabetes-related parameters
Glucose on admission 8.2 (6.55–10.6) mmol/L/
148 (118–191) mg/dL
7.1 (5.9–8.8) mmol/L/
128 (106–159) mg/dL
9.52 (7.7–12.8) mmol/L/
172 (139–231) mg/dL
<0.001
Mean glucose differences from peaks to nadirs (MAGE) 4.89 (±2.18) 4.12 (±1.87) 5.63 (±2.21) <0.001
Glucose (coefficient of variation) 2 0.3 (±0.1) 0.27 (±0.09) 0.32 (±0.09) <0.001
Insulin pre-treatment (including type 1 and pancreatogenic) 173 (21.3%) 173 (21.3%)
Pre-treatment with glucose-lowering agents other than insulin 178 (21.9%) 178 (43%)
Diabetes treatment with dietary measures 62 (7.64%) 62 (15%)

Data is shown as n (%) or mean/median (standard deviation or interquartile range) per group. GC: glucocorticoid. 1 mean GC dose is given as normalized GC dose in mg per prednisolone equivalent per kg per day. 2 CV = SD/mean ∗ 100%.